Jeff Cislini Sells 6,000 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Jeff Cislini sold 6,000 shares of Revolution Medicines stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $50.17, for a total value of $301,020.00. Following the completion of the sale, the general counsel now directly owns 45,634 shares in the company, valued at $2,289,457.78. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Revolution Medicines Stock Performance

Revolution Medicines stock opened at $50.42 on Thursday. Revolution Medicines, Inc. has a 52 week low of $15.44 and a 52 week high of $51.00. The stock has a market capitalization of $8.42 billion, a P/E ratio of -13.85 and a beta of 1.43. The stock has a fifty day moving average of $44.51 and a 200-day moving average of $41.09.

Revolution Medicines (NASDAQ:RVMD) last issued its earnings results on Wednesday, August 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.04). The business had revenue of $1.00 million during the quarter, compared to analyst estimates of $0.81 million. During the same period in the previous year, the firm posted ($0.92) earnings per share. The firm’s quarterly revenue was down 73.8% on a year-over-year basis. On average, research analysts forecast that Revolution Medicines, Inc. will post -3.35 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its stake in shares of Revolution Medicines by 55.8% in the third quarter. GAMMA Investing LLC now owns 620 shares of the company’s stock worth $28,000 after purchasing an additional 222 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in Revolution Medicines by 10.5% during the second quarter. Nisa Investment Advisors LLC now owns 3,378 shares of the company’s stock valued at $131,000 after purchasing an additional 320 shares during the period. Amalgamated Bank boosted its holdings in shares of Revolution Medicines by 7.4% in the second quarter. Amalgamated Bank now owns 5,272 shares of the company’s stock worth $205,000 after acquiring an additional 365 shares during the period. Headlands Technologies LLC boosted its holdings in shares of Revolution Medicines by 140.9% in the first quarter. Headlands Technologies LLC now owns 1,513 shares of the company’s stock worth $49,000 after acquiring an additional 885 shares during the period. Finally, Clear Harbor Asset Management LLC boosted its holdings in shares of Revolution Medicines by 10.2% in the second quarter. Clear Harbor Asset Management LLC now owns 11,224 shares of the company’s stock worth $436,000 after acquiring an additional 1,036 shares during the period. Institutional investors own 94.34% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Jefferies Financial Group assumed coverage on Revolution Medicines in a research note on Monday, July 8th. They issued a “buy” rating and a $63.00 price target on the stock. Barclays raised their price target on Revolution Medicines from $54.00 to $60.00 and gave the company an “overweight” rating in a research note on Friday, September 27th. HC Wainwright reiterated a “buy” rating and set a $56.00 target price on shares of Revolution Medicines in a research note on Monday, August 12th. JPMorgan Chase & Co. reduced their target price on Revolution Medicines from $55.00 to $54.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $61.00 target price on shares of Revolution Medicines in a research note on Monday, October 7th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $54.00.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.